3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Unknown
2
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
35
Lymphoma, Large B-Cell, Diffuse
28
Multiple Myeloma
26
Lymphoma
26
Lymphoma, Non-Hodgkin
21
Leukemia, Myeloid, Acute
21
Leukemia, Lymphocytic, Chronic, B-Cell
21
Neoplasms
20
Myelodysplastic Syndromes
19
Lymphoma, Follicular
18
Recurrence
16
Lymphoma, B-Cell
16
Leukemia
16
Burkitt Lymphoma
16
Lymphoma, Mantle-Cell
15
Triple Negative Breast Neoplasms
14
Ovarian Neoplasms
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Neuroblastoma
10
Lymphoma, B-Cell, Marginal Zone
10
Hodgkin Disease
10
Sarcoma
8
Melanoma
8
Medulloblastoma
8
Rhabdomyosarcoma
7
Myeloproliferative Disorders
7
Leukemia, Biphenotypic, Acute
7
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
6
Interventions
Temozolomide
4
abemaciclib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
vorasidenib
1
pembrolizumab
1
Vorinostat
1
Vincristine
1
Specimen Handling
1
Radiotherapy, Conformal
1
Protons
1
Proton Therapy
1
Procarbazine
1
OKN 007
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Lomustine
1
Irinotecan
1
DNA Methylation
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Biopsy
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Oligodendroglioma
×
Cyclophosphamide
×
Clear all
NCT03152318
2026-03-04
rQNestin
Dana-Farber Cancer Institute
Phase 1
Active not recruiting
62 enrolled